No Data
No Data
Express News | Rani Therapeutics-After Evaluating Ongoing Business Development,Business Outlook,Elected Not to Move Forward With Equity Financing at This Time
Express News | Rani Therapeutics Holdings - After Evaluating Cash Position, Business, Elected Not to Move Forward With Equity Financing at This Time
Express News | Rani Therapeutics Holdings Inc - Had Recently Engaged in Discussions With Various Investors to Explore a Potential Equity Financing.
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $15
Maxim Group analyst Michael Okunewitch maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 26.
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $13
H.C. Wainwright analyst Mitchell Kapoor maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 32
BTIG Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $14
BTIG analyst Julian Harrison maintains $Rani Therapeutics(RANI.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 47.0% and a t